Cargando…
Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer
BACKGROUND: Metformin is a biguanide oral hypoglycaemic agent commonly used for the treatment of type 2 diabetes mellitus. In addition to its anti-diabetic effect, metformin has also been associated with a reduced risk of cancer incidence of a number of solid tumours, including prostate cancer (PCa)...
Autores principales: | Crawley, Danielle, Chandra, Ashish, Loda, Massimo, Gillett, Cheryl, Cathcart, Paul, Challacombe, Ben, Cook, Gary, Cahill, Declan, Santa Olalla, Aida, Cahill, Fidelma, George, Gincy, Rudman, Sarah, Van Hemelrijck, Mieke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520293/ https://www.ncbi.nlm.nih.gov/pubmed/28732480 http://dx.doi.org/10.1186/s12885-017-3458-3 |
Ejemplares similares
-
Research engagement among black men with prostate cancer
por: Toms, Charlotte, et al.
Publicado: (2016) -
Invadopodia play a role in prostate cancer progression
por: Manuelli, Valeria, et al.
Publicado: (2022) -
Confirmatory biopsy for the assessment of prostate cancer in men considering active surveillance: reference centre experience
por: Bosco, Cecilia, et al.
Publicado: (2016) -
King’s Health Partners’ Prostate Cancer Biobank (KHP PCaBB)
por: Saifuddin, S. R., et al.
Publicado: (2017) -
Are you now a good surgeon? T2 positive margin status as a quality outcome measure following radical prostatectomy
por: Damani, Arees, et al.
Publicado: (2016)